Akebia Therapeutics (AKBA) Gross Margin (2019 - 2025)
Historic Gross Margin for Akebia Therapeutics (AKBA) over the last 7 years, with Q3 2025 value amounting to 84.03%.
- Akebia Therapeutics' Gross Margin rose 218700.0% to 84.03% in Q3 2025 from the same period last year, while for Sep 2025 it was 78.99%, marking a year-over-year decrease of 4379800.0%. This contributed to the annual value of 60.56% for FY2024, which is 7020500.0% up from last year.
- Akebia Therapeutics' Gross Margin amounted to 84.03% in Q3 2025, which was up 218700.0% from 84.12% recorded in Q2 2025.
- In the past 5 years, Akebia Therapeutics' Gross Margin registered a high of 114.53% during Q4 2023, and its lowest value of 0.79% during Q2 2021.
- Its 5-year average for Gross Margin is 61.35%, with a median of 62.16% in 2024.
- In the last 5 years, Akebia Therapeutics' Gross Margin skyrocketed by 1696000bps in 2021 and then crashed by -583300bps in 2024.
- Quarter analysis of 5 years shows Akebia Therapeutics' Gross Margin stood at 17.42% in 2021, then skyrocketed by 509bps to 106.15% in 2022, then rose by 8bps to 114.53% in 2023, then crashed by -51bps to 56.2% in 2024, then soared by 50bps to 84.03% in 2025.
- Its Gross Margin was 84.03% in Q3 2025, compared to 84.12% in Q2 2025 and 86.7% in Q1 2025.